Amgen pleads guilty to improper marketing of anemia drug Aranesp
By Chad Terhune, Los Angeles Times
December 18, 2012, 4:46 p.m.
Biotech giant Amgen Inc. pleaded guilty in federal court to improper marketing of its anemia drug Aranesp and has agreed to pay $762 million in criminal fines and civil settlements to resolve complaints from company whistle-blowers.
Amgen agreed Tuesday to pay a $150-million criminal penalty and $612 million to resolve 11 related whistle-blower complaints. Ten of the complaints remain under seal until the court accepts the settlement.
Tuesday, December 18, 2012
BIG PHARMA'S CRIMINAL SAGA CONTINUES
Someone should do an expose of all the fines Big Pharma has paid since 2000. The total amount of fines for 2012 alone is now over $7 Billion.
Subscribe to:
Post Comments (Atom)
Posts
1 comment:
Obamacare is largely a sellout to Big Pharma, now that you mention the subject.
http://www.correntewire.com/obamacare_architect_leaves_senate_for_big_pharma
Post a Comment